Publications from the Centre for Immuno-Oncology
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Ruiz-Fernández de Córdoba B. et al, (2025), Signal transduction and targeted therapy, 10
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.
Lee CY. et al, (2025), Cancer immunology research
Strict advantage of complex quantum theory in a communication task
Elliott TJ., (2025), Physical Review A, 111
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Skolariki A. et al, (2025), Mol Oncol
Immunocytokines and cytokine neutralization for cancer immunotherapy
Berraondo P. et al, (2025), Trends in Cancer
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Vadibeler S. et al, (2025), Matrix biology : journal of the International Society for Matrix Biology
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Heras-Murillo I. et al, (2025), Nature Communications, 16
Barriers to publishing early phase clinical trials: the oncologists' perspective.
Lucassen MJJ. et al, (2025), The oncologist, 30
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.
Galvez-Cancino F. et al, (2025), Immunity
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)